Profusa Expands Sales Footprint with New Distributor for Lumee™ Oxygen Platform in Europe
Profusa, Inc. (PFSA)
Company Research
Source: GlobeNewswire
Initial target markets for commercialization include Germany, the Benelux countries, Austria, the United Kingdom, and Scandinavia Expands distributor channel coverage to ~35% of European Union population with ~300,000 annual endovascular procedures BERKELEY, Calif, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (Nasdaq: PFSA), a commercial stage digital health company pioneering the next generation of technology platform enabling the continuous monitoring of an individual’s biochemistry, announces it has expanded its commercial footprint for its Lumee Oxygen platform in Europe with the signing of a letter of intent to establish logistics and commercialization footprint with Angiopro GmbH (“Angiopro”). Initial markets targeted for launch and commercialization of the Lumee platform include Germany, the Benelux countries, Austria, the United Kingdom, and Scandinavia. The arrangement with AngioPro builds upon Profusa’s distributor sales coverage in Eur
Show less
Read more
Impact Snapshot
Event Time:
PFSA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PFSA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PFSA alerts
High impacting Profusa, Inc. news events
Weekly update
A roundup of the hottest topics
PFSA
News
- Profusa to Present Late Breaking U.S.-Based Clinical Trial Update at Paris Vascular Insights 2025GlobeNewswire
- Profusa (NASDAQ:PFSA) is now covered by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>. They set a "sell (e+)" rating on the stock.MarketBeat
- Profusa Announces Third Quarter Business and Financial Highlights [Yahoo! Finance]Yahoo! Finance
- Profusa Announces Third Quarter Business and Financial HighlightsGlobeNewswire
- Profusa Outlines Potential Path to $250 Million Revenue by 2030, Driven by Sequential Lumee™ Oxygen and Glucose Monitoring LaunchesGlobeNewswire